SCHEMBL4738587

SCHEMBL4738587

CCN(C(=O)OC(C)(C)C)c1ccc(N)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 5/20 0.43
ALDH1A1 P00352 3/20 0.43
CYP3A4 P08684 3/20 0.43
MAPK1 P28482 2/20 0.43
PSMD14 O00487 1/20 0.43
RECQL P46063 1/20 0.43
GFER P55789 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
GLA P06280 1/20 0.40
HTT P42858 1/20 0.39
KDM4E B2RXH2 1/20 0.38
NPC1 O15118 1/20 0.38
MAPT P10636 1/20 0.38
RAB9A P51151 1/20 0.38
MAOA P21397 2/20 0.38
CYP2D6 P10635 1/20 0.38
HTR3A P46098 1/20 0.38
HRH3 Q9Y5N1 1/20 0.38
LMNA P02545 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18011040 0.89 CYP3A4 (0.41) TSHRALDH1A1CYP3A4MAPK1PSMD14
SCHEMBL16640702 0.89 PHLPP2 (0.37) TSHRALDH1A1CYP3A4MAPK1PSMD14
SCHEMBL3894800 0.85 TSHR (0.42) TSHRALDH1A1GLAHTTKDM4E
SCHEMBL5264223 0.85 AOC3 (0.41) TSHRALDH1A1L3MBTL1GLAHTT
SCHEMBL20955433 0.85 CYP3A4 (0.44) TSHRALDH1A1CYP3A4MAPK1PSMD14
SCHEMBL28836938 0.84 SSTR4 (0.38) TSHRALDH1A1CYP3A4MAPK1PSMD14
SCHEMBL27696712 0.84 CYP3A4 (0.36) TSHRALDH1A1CYP3A4MAPK1PSMD14
SCHEMBL16142413 0.84 L3MBTL1 (0.40) ALDH1A1CYP3A4L3MBTL1NPC1MAPT
SCHEMBL16640701 0.84 NR1H4 (0.38)
SCHEMBL3375082 0.84 MLYCD (0.38) CYP3A4MLYCDCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111051309-B Triazolotriazine derivatives useful as A2A receptor antagonists 浙江春禾医药科技有限公司 2023-05-26 CN disclosed
US-20150065490-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2015-03-05 US disclosed
CN-102625708-A Pi3 kinase inhibitors and uses thereof AVILA THERAPEUTICS INC 2012-08-01 CN disclosed
WO-2008086462-A2 AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF β-CANTENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS WYETH (US) 2008-07-17 WO disclosed
US-20060089398-A1 Isoxazole carboxamide derivatives as ghrelin receptor modulators NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2006-04-27 US disclosed
CN-1098841-C Novel amide derivatives and pharmaceutical compositions thereof YAMANOUCHI PHARMA CO LTD (JP) 2003-01-15 CN disclosed
CN-1244193-A Novel amide derivatives and medicinal compositions thereof YAMANOUCHI PHARMA CO LTD (JP) 2000-02-09 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060089398-A1 Isoxazole carboxamide derivatives as ghrelin receptor modulators GPR119, GIPR, GLP1R TSHR 285/4885ALDH1A1 3320/4885CYP3A4 3261/4885
US-20150065490-A1 ORGANIC COMPOUNDS ADRB2, ADRA2C, ADRB1 TSHR 1097/4885ALDH1A1 226/4885CYP3A4 262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.